CYTK Quote, Financials, Valuation and Earnings

Bristol-Myers Squibb has a net margin of -10220.14% compared to Cytokinetics's net margin of 21.93%. Cytokinetics's return on equity of -- beat Bristol-Myers Squibb's return on equity of 32.01%.

Cytokinetics has a consensus price target of $74.52, signalling upside risk potential of 128.6%. On the other hand Bristol-Myers Squibb has an analysts' consensus of $57.19 which suggests that it could grow by 18.69%. Given that Cytokinetics has higher upside potential than Bristol-Myers Squibb, analysts believe Cytokinetics is more attractive than Bristol-Myers Squibb.

Cytokinetics has a beta of 0.808, which suggesting that the stock is 19.173% less volatile than S&P 500. In comparison Bristol-Myers Squibb has a beta of 0.392, suggesting its less volatile than the S&P 500 by 60.827%.

Cytokinetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bristol-Myers Squibb offers a yield of 5.06% to investors and pays a quarterly dividend of $0.62 per share. Cytokinetics pays -- of its earnings as a dividend. Bristol-Myers Squibb pays out -54.35% of its earnings as a dividend.

Cytokinetics quarterly revenues are $1.6M, which are smaller than Bristol-Myers Squibb quarterly revenues of $11.2B. Cytokinetics's net income of -$161.4M is lower than Bristol-Myers Squibb's net income of $2.5B. Notably, Cytokinetics's price-to-earnings ratio is -- while Bristol-Myers Squibb's PE ratio is 18.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cytokinetics is 193.75x versus 2.06x for Bristol-Myers Squibb. Usually stocks with elevated PS ratios are considered overvalued.

Edgewise Therapeutics has a net margin of -10220.14% compared to Cytokinetics's net margin of --. Cytokinetics's return on equity of -- beat Edgewise Therapeutics's return on equity of --.

Cytokinetics has a consensus price target of $74.52, signalling upside risk potential of 128.6%. On the other hand Edgewise Therapeutics has an analysts' consensus of $40.80 which suggests that it could grow by 166.53%. Given that Edgewise Therapeutics has higher upside potential than Cytokinetics, analysts believe Edgewise Therapeutics is more attractive than Cytokinetics.

Cytokinetics has a beta of 0.808, which suggesting that the stock is 19.173% less volatile than S&P 500. In comparison Edgewise Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Cytokinetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edgewise Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cytokinetics pays -- of its earnings as a dividend. Edgewise Therapeutics pays out -- of its earnings as a dividend.

Cytokinetics quarterly revenues are $1.6M, which are larger than Edgewise Therapeutics quarterly revenues of --. Cytokinetics's net income of -$161.4M is lower than Edgewise Therapeutics's net income of -$40.8M. Notably, Cytokinetics's price-to-earnings ratio is -- while Edgewise Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cytokinetics is 193.75x versus -- for Edgewise Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Gilead Sciences has a net margin of -10220.14% compared to Cytokinetics's net margin of 19.72%. Cytokinetics's return on equity of -- beat Gilead Sciences's return on equity of 32.29%.

Cytokinetics has a consensus price target of $74.52, signalling upside risk potential of 128.6%. On the other hand Gilead Sciences has an analysts' consensus of $115.04 which suggests that it could grow by 10.81%. Given that Cytokinetics has higher upside potential than Gilead Sciences, analysts believe Cytokinetics is more attractive than Gilead Sciences.

Cytokinetics has a beta of 0.808, which suggesting that the stock is 19.173% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.263, suggesting its less volatile than the S&P 500 by 73.697%.

Cytokinetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences offers a yield of 2.99% to investors and pays a quarterly dividend of $0.79 per share. Cytokinetics pays -- of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend.

Cytokinetics quarterly revenues are $1.6M, which are smaller than Gilead Sciences quarterly revenues of $6.7B. Cytokinetics's net income of -$161.4M is lower than Gilead Sciences's net income of $1.3B. Notably, Cytokinetics's price-to-earnings ratio is -- while Gilead Sciences's PE ratio is 21.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cytokinetics is 193.75x versus 4.56x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of -10220.14% compared to Cytokinetics's net margin of 21.68%. Cytokinetics's return on equity of -- beat Eli Lilly and's return on equity of 78.25%.

Cytokinetics has a consensus price target of $74.52, signalling upside risk potential of 128.6%. On the other hand Eli Lilly and has an analysts' consensus of $978.82 which suggests that it could grow by 29.55%. Given that Cytokinetics has higher upside potential than Eli Lilly and, analysts believe Cytokinetics is more attractive than Eli Lilly and.

Cytokinetics has a beta of 0.808, which suggesting that the stock is 19.173% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.479, suggesting its less volatile than the S&P 500 by 52.104%.

Cytokinetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.72% to investors and pays a quarterly dividend of $1.50 per share. Cytokinetics pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Cytokinetics quarterly revenues are $1.6M, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Cytokinetics's net income of -$161.4M is lower than Eli Lilly and's net income of $2.8B. Notably, Cytokinetics's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 61.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cytokinetics is 193.75x versus 13.93x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.